Oct 04, 2021 7:30 am EDT Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
Oct 01, 2021 6:14 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sep 29, 2021 3:30 am EDT Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
Sep 27, 2021 8:30 am EDT European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Sep 03, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sep 02, 2021 8:30 am EDT Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
Aug 09, 2021 4:02 pm EDT Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
Aug 09, 2021 4:01 pm EDT Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
Aug 02, 2021 6:00 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 02, 2021 8:30 am EDT Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021